Clinical Trial Detail

NCT ID NCT02548962
Title Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Pharmacyclics
Indications

multiple myeloma

Therapies

Ibrutinib

Dexamethasone + Pomalidomide

Age Groups: adult

No variant requirements are available.